Clinical Trial Update: BI 44370 TA in Acute Migraine Attack [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BI 44370 TA for acute migraine attacks has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• BI 44370 TA

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Migraine Disorders | Phase 2 | Status: COMPLETED